BrainStorm Granted SME Status by the European Medicines Agency

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agencys (EMA) Micro, Small and Medium-Sized Enterprise (SME) office .